Keywords: Hyperpolarized MR (Non-Gas), Non-Proton, Fumarate, Necrosis, Treatment Response
Motivation: Clinical translation of hyperpolarized 13C-fumarate has the potential to enable early, non-invasive assessment of treatment response in cancer.
Goal(s): To advance a novel hyperpolarized probe from the laboratory to the clinic.
Approach: Translation involved optimizing clinical scale hyperpolarization, establishing an imaging protocol at clinical field strength (3T), preclinical toxicology and first in-human injections.
Results: 13C-fumarate showed good hyperpolarization properties and the imaging protocol achieved sufficient spectral separation of peaks and spatial separation of phantoms respectively. Toxicological assessment demonstrated the safety of 13C-fumarate, no adverse events observed in rodents and humans have so far been observed.
Impact: While promising preclinical molecules exist, clinical hyperpolarized 13C MRI lacks probe versatility due to a complex, unclear translation process. This study on fumarate narrows the gap between preclinical and clinical utility and fosters transparent clinical translation pipelines for the field.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords